Downsizing Treatment with Tyrosine Kinase Inhibitors in Patients with Advanced Gastrointestinal Stromal Tumors Improved Resectability

BACKGROUND: Gastrointestinal stromal tumors (GISTs) express the receptor tyrosine kinase KIT. Most GISTs have mutations in the KIT or PDGFRA gene, causing activation of tyrosine kinase. Imatinib, a tyrosine kinase inhibitor (TKI), is the first-line palliative treatment for advanced GISTs. Sunitinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Sjölund, Katarina, Andersson, Anna, Nilsson, Erik, Nilsson, Ola, Ahlman, Håkan, Nilsson, Bengt
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917560/
https://www.ncbi.nlm.nih.gov/pubmed/20512492
http://dx.doi.org/10.1007/s00268-010-0639-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917560/
https://www.ncbi.nlm.nih.gov/pubmed/20512492
http://dx.doi.org/10.1007/s00268-010-0639-5

Ejemplares similares